Legal peptide prices are what FDA-approved peptide drugs, compounded peptides that FDA allows pharmacies to make, and cosmetic peptide products cost in the US, as published by the seller.
At a glance
Compounded NAD+ and glutathione listed at $49 to $159 a month on Oct 19, 2026; sermorelin and PT-141, legal status not confirmed, at up to $249 [24][27][32].
What you will pay, seller by sellerBrand Vyleesi is $99 per 4-dose box through its maker without insurance [1], but it is priced per box, not per month.
Brand Vyleesi compared with compounded PT-141Compounded tesamorelin has no clear legal basis because FDA regulates it as a biologic [11].
Egrifta WR and compounded tesamorelinBPC-157 and other peptides that cannot be legally compounded are left out, and so are research-use-only prices.
What is not on this tracker, and why
Legal peptide prices at a glance
| Product | Price range | Legal status | Sources |
|---|---|---|---|
| Vyleesi (bremelanotide), brand | $99 per 4-dose box through the maker without insurance; $1,428.26 retail for 4 | FDA-approved for low sexual desire in premenopausal women only | [1][2][5] |
| PT-141, compounded | $129 to $249 a month at standard rates | We did not confirm FDA's position on compounded bremelanotide | [23][32] |
| Egrifta WR (tesamorelin), brand | $11,029.87 to $18,218.03 per kit | FDA-approved for excess abdominal fat in adults with HIV and lipodystrophy only | [7][6][8] |
| Forzinity (elamipretide), brand | Up to nearly $800,000 a year | FDA accelerated approval for Barth syndrome only | [13][14] |
| Sermorelin, compounded | $99 to $225 a month at standard rates | Not confirmed: we found no FDA statement on compounding it | [15][19][46] |
| NAD+, compounded | $99 to $159 a month for telehealth injections (IvyRx lists $179 with no term); Defy Medical vials $120 to $190 each; $499 to $999 per IV session at one mobile chain | Category 1: may be compounded with a prescription | [22][27][20][35][36][43] |
| Glutathione, compounded | $49 to $99 a month (IvyRx lists $179 with no term) | Category 1: may be compounded with a prescription | [24][29][20][43] |
| GHK-Cu cream, compounded | $89 to $129 a month, month to month | Category 1 for non-injectable forms only | [25][30][43] |
| Copper peptide serum, cosmetic | $32 to $93 per bottle | Sold as a cosmetic, not a drug | [38][40] |
What you will pay, seller by seller
The table has 34 price rows from 18 sellers or channels, grouped by product. Prices are as each seller published them on Oct 19, 2026. We name sellers in plain text and do not link to them from the table. A row is not a recommendation. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [54].
| Product | Form | Seller or channel | Price as published | What the price covers | Checked | Source | FDA warning letter |
|---|---|---|---|---|---|---|---|
| Vyleesi (bremelanotide), FDA-approved | 1.75 mg autoinjector, box of 4 | Maker's program (BlinkRx pharmacy) | $99 per 4-dose box without insurance coverage; most commercially insured pay $0 | Drug only, home delivery; copay help limited to 2 fills per 30 days; government-insured excluded | Oct 19, 2026 | Cosette Pharmaceuticals [1] | Not applicable |
| Vyleesi (bremelanotide), FDA-approved | 4 x 1.75 mg autoinjectors | Retail pharmacy cash price (SingleCare listing) | $1,428.26 retail; $983.62 with SingleCare | Drug only | Oct 19, 2026 | SingleCare [2] | Not applicable |
| Vyleesi (bremelanotide), FDA-approved | Autoinjector | Retail cash estimate (GoodRx article) | About $290 per autoinjector without insurance | Drug only | Oct 19, 2026 | GoodRx [3] | Not applicable |
| PT-141, compounded (FDA position not confirmed) | Injection, nasal spray or troche | PepScribe (telehealth) | From $129 a month | Drug, clinical care, shipping; no membership fee | Oct 19, 2026 | PepScribe [23] | None found |
| PT-141, compounded (FDA position not confirmed) | Form not stated | Hone Health (telehealth) | $130 a month plus membership ($25 a month Basic or $155 a month Premium); $65 biomarker test | Drug; membership and test extra | Oct 19, 2026 | Hone Health [18] | None found |
| PT-141, compounded (FDA position not confirmed) | Injection | PlexusDx (telehealth) | $189 month to month; $159 a month on a 12-month plan ($1,908 up front) | Visit, prescription, drug, shipping; plans paid up front and auto-renew | Oct 19, 2026 | PlexusDx [28] | None found |
| PT-141, compounded (FDA position not confirmed) | Injection, as needed | Rx.com (telehealth) | $249 for one month; 12-month plan $40 first month, then $160 a month | Consult, care-team messaging, 2-day shipping; billed every 4 to 48 weeks by plan | Oct 19, 2026 | Rx.com (Rx Platform LLC) [32] | None found |
| PT-141, compounded (FDA position not confirmed) | Nasal spray, 30-day supply | MintRx (telehealth) | $180 per 30-day supply | Not itemized | Oct 19, 2026 | MintRx [34] | None found |
| Egrifta WR (tesamorelin), FDA-approved | 11.6 mg kit | Retail pharmacy cash price (SingleCare listing) | $18,218.03 retail per kit; $11,037.51 with SingleCare | Drug only; days of supply per kit not stated | Oct 19, 2026 | SingleCare [6] | Not applicable |
| Egrifta WR (tesamorelin), FDA-approved | 11.6 mg kit | Retail cash price (Drugs.com price guide) | From $11,029.87 per kit | Drug only | Oct 19, 2026 | Drugs.com [7] | Not applicable |
| Forzinity (elamipretide), FDA-approved | Injection | Specialty drug (Reuters report) | Up to nearly $800,000 a year | Not stated whether list price or net | Oct 19, 2026 | Reuters (republished by SRN News) [13] | Not applicable |
| Sermorelin, compounded (legal status not confirmed) | Sublingual lozenge | Strut Health (telehealth) | $99 a month | Drug, physician consults, shipping; monthly auto-refill | Oct 19, 2026 | Strut Health [15] | Feb 20, 2026, over GLP-1 marketing that suggested Strut was the compounder [41] |
| Sermorelin, compounded (legal status not confirmed) | Injection, monthly vial | Strut Health (telehealth) | $119 a month | Drug, physician consults, shipping; monthly auto-refill | Oct 19, 2026 | Strut Health [15] | Feb 20, 2026, over GLP-1 marketing that suggested Strut was the compounder [41] |
| Sermorelin, compounded (legal status not confirmed) | Injection | PepScribe (telehealth) | From $99 a month | Drug, clinician care, syringes, shipping; no membership fee | Oct 19, 2026 | PepScribe [21] | None found |
| Sermorelin, compounded (legal status not confirmed) | Injection | Rx.com (telehealth) | $179 for one month; $99 a month on 3, 6 or 12-month plans ($297, $594 or $1,188 up front) | Provider review, shipping; no membership fee. Names Manifest Pharmacy as dispenser | Oct 19, 2026 | Rx.com (Rx Platform LLC) [31] | None found |
| Sermorelin, compounded (legal status not confirmed) | Injection | PlexusDx (telehealth) | $159 month to month; $119 a month on a 12-month plan ($1,428 up front) | Visit, prescription, drug, shipping; plans auto-renew | Oct 19, 2026 | PlexusDx [26] | None found |
| Sermorelin, compounded (legal status not confirmed) | Sublingual tablet | Haven Health (telehealth) | $163 a month on a 3-month plan ($489); $139 a month on a 6-month plan ($829) | Drug, provider check-ins, shipping; standard lab panel $89 extra | Oct 19, 2026 | Haven Health [33] | None found |
| Sermorelin, compounded (legal status not confirmed) | Injection | Hone Health (telehealth) | $175 a month | Unclear whether a membership ($25 or $155 a month) is extra; $65 biomarker test listed | Oct 19, 2026 | Hone Health [17] | None found |
| Sermorelin, compounded (legal status not confirmed) | Injection | IvyRx (telehealth) | $225 for one month; $175 a month on a 6-month plan ($1,050 up front) | Drug, provider review, injection supplies, cold shipping | Oct 19, 2026 | Ivy RX PLLC [19] | None found |
| NAD+, compounded (Category 1) | Injection | PepScribe (telehealth) | From $99 a month (injection or nasal spray) | Drug, clinical care, supplies; no membership fee | Oct 19, 2026 | PepScribe [22] | None found |
| NAD+, compounded (Category 1) | Injection, 500 mg vial | Strut Health (telehealth) | $149 a month | Drug, physician consults, shipping; monthly auto-refill | Oct 19, 2026 | Strut Health [16] | Feb 20, 2026, over GLP-1 marketing that suggested Strut was the compounder [41] |
| NAD+, compounded (Category 1) | Injection | PlexusDx (telehealth) | $159 month to month; $119 a month on a 12-month plan ($1,428 up front) | Visit, prescription, drug, shipping | Oct 19, 2026 | PlexusDx [27] | None found |
| NAD+, compounded (Category 1) | Injection | IvyRx (telehealth) | $179 | Not stated; term (monthly or one-time) not stated | Oct 19, 2026 | Ivy RX PLLC [20] | None found |
| NAD+, compounded (Category 1) | Injection vials; nasal spray | Defy Medical (clinic and telehealth) | Vials $120 to $190 (500 mg $120; 1,000 mg $182); nasal spray $55 or $200 | Drug only; consult or membership not stated. Undated price sheet posted May 2026 | Oct 19, 2026 | Defy Medical [35] | None found |
| NAD+ IV, compounded (Category 1) | IV infusion at home or office | Drip Hydration (mobile IV) | $499 (250 mg), $799 (500 mg) or $999 (1,000 mg) per session; memberships $749 to $4,799 a month | Drug, nurse visit, monitoring | Oct 19, 2026 | Drip Hydration [36] | None found |
| NAD+ IV, compounded (Category 1) | IV add-on | AZ IV Medics (one Scottsdale clinic) | $75 to $675 depending on dose | Not stated; clinic adds a $9 medical review fee and a $20 yearly good faith exam | Oct 19, 2026 | AZ IV Medics [37] | Not searched |
| Glutathione, compounded (Category 1) | Injection, oral or sublingual | PepScribe (telehealth) | From $49 a month (form not tied to the starting price) | Drug, clinician care, shipping; no membership fee | Oct 19, 2026 | PepScribe [24] | None found |
| Glutathione, compounded (Category 1) | Injection | PlexusDx (telehealth) | $99 month to month; $69 a month on a 12-month plan ($828 up front) | Visit, prescription, drug, shipping; plans auto-renew | Oct 19, 2026 | PlexusDx [29] | None found |
| Glutathione, compounded (Category 1) | Injection | IvyRx (telehealth) | $179 | Not stated | Oct 19, 2026 | Ivy RX PLLC [20] | None found |
| GHK-Cu cream, compounded (Category 1, non-injectable) | Topical cream | PepScribe (telehealth) | From $89 a month | Drug, clinician care, shipping; no membership | Oct 19, 2026 | PepScribe [25] | None found |
| GHK-Cu cream, compounded (Category 1, non-injectable) | Topical cream | PlexusDx (telehealth) | $89 to $129 a month month to month, by strength (0.2% to 2%); from $59 a month on a 12-month 0.2% plan ($708 up front) | Provider visit, prescription, drug, shipping; plans auto-renew | Oct 19, 2026 | PlexusDx [30] | None found |
| Copper peptide serum, cosmetic (not a drug) | 1% serum, 30 mL | The Ordinary (retail) | $32.00 | Product only; no prescription | Oct 19, 2026 | The Ordinary (DECIEM) [38] | Not applicable |
| Copper peptide serum, cosmetic (not a drug) | Serum (size tied to price not clear) | NIOD (retail) | $62.00 (out of stock Oct 19, 2026) | Product only; no prescription | Oct 19, 2026 | NIOD [39] | Not applicable |
| Copper peptide serum, cosmetic (not a drug) | 1% gel, 15 mL | NIOD (retail) | $93.00 | Product only; no prescription | Oct 19, 2026 | NIOD [40] | Not applicable |
Eden is not in the table. Its site would not load when we checked, and the only sermorelin and NAD+ prices we found for it came from a competitor's January 2026 article. Eden received an FDA warning letter on June 8, 2026 over compounded GLP-1 labels that suggested Eden was the compounder and a claim about "FDA-licensed 503(a) outsourcing facilities" [42]. See our Eden review.
Brand Vyleesi compared with compounded PT-141
Bremelanotide is the active ingredient in Vyleesi. The brand is FDA-approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and not for men, postmenopausal women or to enhance sexual performance [5]. Through the maker's program, a 4-dose box is $99 for people without insurance coverage, and the maker says most people with commercial insurance pay $0 [1]. At a retail pharmacy without that program, SingleCare lists $1,428.26 for 4 autoinjectors [2].
Compounded PT-141 plans list at $129 to $249 a month [23][32]. These are different units. Vyleesi is priced per box of four doses, while compounded plans are priced per month, and the sellers do not say how many doses a month includes. Compounded PT-141 is not FDA-approved, and we did not confirm FDA's position on compounding bremelanotide. FDA has sent warning letters to online sellers of "research use only" PT-141 [49].
Egrifta WR and compounded tesamorelin
Egrifta WR is FDA-approved only to reduce excess abdominal fat in adults with HIV who have lipodystrophy, and the label says it is not for weight loss [8]. Retail cash prices run from $11,029.87 per 11.6 mg kit on Drugs.com to $18,218.03 per kit at SingleCare's listed retail price, or $11,037.51 with SingleCare [7][6]. SingleCare does not say how many days a kit lasts. A GoodRx listing showed a higher figure without a stated quantity, so we left it out.
Compounded tesamorelin is offered online, but it has no clear legal basis. Egrifta's application was deemed a biologics license on March 23, 2020 [12], and FDA says these transitioned biologics are not eligible for 503A or 503B compounding [11]. We do not list compounded tesamorelin prices for that reason. More on the drug: tesamorelin.
Hidden costs
- Memberships. Hone Health lists PT-141 at $130 a month plus a membership of $25 or $155 a month [18].
- Labs. Haven Health charges $89 for a standard lab panel on top of sermorelin [33]; Hone lists a $65 biomarker test [17].
- Up-front plans. The lowest monthly rates often need prepayment: $1,428 for 12 months of sermorelin or NAD+ at PlexusDx [26][27], or $1,908 for 12 months of PT-141 [28]. Plans at PlexusDx auto-renew.
- Intro prices. Rx.com's 12-month PT-141 plan starts at $40 for the first month, then $160 a month [32].
- Dose. Drip Hydration's NAD+ IV is $499 for 250 mg and $999 for 1,000 mg [36]; AZ IV Medics lists $75 to $675 depending on dose, plus a $9 review fee and a $20 yearly exam [37].
- Copay help limits. Vyleesi's copay help is limited to 2 fills per 30 days, and people with government insurance are excluded [1].
Ask which pharmacy makes the drug. Of the compounded-drug sellers in the table, only Rx.com named its dispensing pharmacy on its site: Manifest Pharmacy [31]. For glutathione, ask whether the pharmacy uses pharmaceutical-grade ingredients: CDC linked 2026 illnesses in Texas, Washington, Florida and New York to compounded glutathione injections made with ingredients intended for dietary supplements [47].
Insurance coverage
Vyleesi: Cigna covers it with prior authorization for premenopausal women with the approved diagnosis, approving an initial 8 weeks and then 6 months at a time; it does not cover men or postmenopausal women, and many plans exclude drugs for sexual dysfunction [4]. Egrifta: Centene's PA Health & Wellness plan covers Egrifta SV and WR with prior authorization for excess abdominal fat in adults with HIV and lipodystrophy, for 6 months at first and 12 months on renewal [10]. The maker runs a co-pay program for commercially insured patients and a patient assistance program that gives qualifying patients its drugs at no cost; it does not publish dollar caps [9].
Compounded peptides are cash-pay in the listings we checked. If you plan to use an HSA or FSA, ask your plan administrator first. For other cash-pay injections, see wellness injections.
What is not on this tracker, and why
BPC-157, TB-500, KPV, MOTS-c, CJC-1295, ipamorelin and the other peptides marked not legal in our peptide FDA status tracker have no price here. None is FDA-approved, and none is in Category 1, so a 503A pharmacy may not compound them [43]. FDA's April 2026 removal of 12 peptides from Category 2 did not change that [45]. Retatrutide is not approved and cannot be compounded [51]; see retatrutide.
We left out "research use only" prices on purpose. Products sold with that label are not a legal source for human use, and FDA has said so in warning letters [50]. One seller in our table, IvyRx, listed BPC-157 under peptides on its home page with no price when we checked [20]; BPC-157 is not eligible for 503A compounding [43]. For the full picture of BPC-157, see BPC-157 legal status and evidence.
Athletes: IV infusions over 100 mL in 12 hours, which can include large NAD+ or glutathione drips, are banned by WADA outside hospital treatment, surgery or clinical diagnostics [48]. Related pages: NAD+ injections, sermorelin.
How we check prices
We opened each seller's own product page on Oct 19, 2026 and recorded the price, form, term and what the price covers as published. Where a seller's page would not load or showed no price, we left the seller out rather than use a third-party figure, except for retail cash prices from SingleCare, Drugs.com and GoodRx and a Reuters report of the Forzinity price, which we label. We list a product only if it has a legal route under FDA's rules [44], and we state the status in the product name. We checked each seller except AZ IV Medics against FDA warning letters. Prices change; email corrections through our contact page. How we earn money: our disclosure.
Questions people ask
How much do peptides cost?
Compounded NAD+ and glutathione, which FDA allows pharmacies to make with a prescription, list at $49 to $159 a month at telehealth companies' standard rates, checked Oct 19, 2026 [24][27][43]. Compounded sermorelin and PT-141, whose legal status we could not confirm, list at $99 to $249 a month [15][32]. FDA-approved Vyleesi is $99 per 4-dose box through its maker without insurance [1], and Egrifta WR runs $11,029.87 to $18,218.03 per kit at retail cash prices [7][6].
How much does Vyleesi cost?
How much does PT-141 cost?
How much do glutathione injections cost?
How much does GHK-Cu cost?
How much do ipamorelin, TB-500 or MOTS-c cost?
Is peptide therapy covered by insurance?
How much does Egrifta (tesamorelin) cost?
Sources
54 cited
- Vyleesi official site: savings and cost. Cosette Pharmaceuticals, accessed 2026-10-19.
- Vyleesi prices. SingleCare, Oct 18, 2026.
- How much is Vyleesi without insurance?. GoodRx, Jun 29, 2026.
- Bremelanotide coverage policy (IP 0117). Cigna, Apr 1, 2026.
- Vyleesi prescribing information. FDA Label (Palatin Technologies), Jan 10, 2025.
- Egrifta WR prices. SingleCare, accessed 2026-10-19.
- Egrifta WR price guide. Drugs.com, accessed 2026-10-19.
- Egrifta WR prescribing information. FDA, Mar 2025.
- THERA patient support. Theratechnologies, accessed 2026-10-19.
- Tesamorelin (Egrifta SV, Egrifta WR) pharmacy policy. Centene / PA Health & Wellness, Jul 2025.
- Notice to compounders: changes that affect compounding on March 23, 2020. FDA, Mar 5, 2020.
- List of approved NDAs for biological products deemed to be BLAs on March 23, 2020. FDA, Apr 2, 2020.
- Exclusive: US FDA cleared pricey rare disease drug over reviewer objections. Reuters (republished by SRN News), Nov 5, 2025.
- FDA grants accelerated approval to first treatment for Barth syndrome. FDA, Sep 19, 2025.
- Sermorelin. Strut Health, accessed 2026-10-19.
- NAD+. Strut Health, accessed 2026-10-19.
- Sermorelin. Hone Health, accessed 2026-10-19.
- PT-141. Hone Health, accessed 2026-10-19.
- Sermorelin cost per month. Ivy RX PLLC, accessed 2026-10-19.
- IvyRx home page. Ivy RX PLLC, accessed 2026-10-19.
- Sermorelin. PepScribe, accessed 2026-10-19.
- NAD+. PepScribe, accessed 2026-10-19.
- PT-141. PepScribe, accessed 2026-10-19.
- Glutathione. PepScribe, accessed 2026-10-19.
- GHK-Cu. PepScribe, accessed 2026-10-19.
- Sermorelin. PlexusDx, accessed 2026-10-19.
- NAD+. PlexusDx, accessed 2026-10-19.
- PT-141. PlexusDx, accessed 2026-10-19.
- Glutathione. PlexusDx, accessed 2026-10-19.
- GHK-Cu Rx. PlexusDx, accessed 2026-10-19.
- Sermorelin. Rx.com (Rx Platform LLC), accessed 2026-10-19.
- PT-141. Rx.com (Rx Platform LLC), accessed 2026-10-19.
- Sermorelin dissolvable. Haven Health, accessed 2026-10-19.
- PT-141. MintRx, accessed 2026-10-19.
- NAD+ price sheet. Defy Medical, May 2026.
- NAD+ IV therapy. Drip Hydration, accessed 2026-10-19.
- IV therapy Scottsdale. AZ IV Medics, accessed 2026-10-19.
- Multi-Peptide + Copper Peptides 1% Serum. The Ordinary (DECIEM), accessed 2026-10-19.
- Copper Amino Isolate Serum 3 1:1. NIOD, accessed 2026-10-19.
- Copper Amino Isolate Lipid 1%. NIOD, accessed 2026-10-19.
- Warning letter: Strut Health LLC dba Strut. FDA, Feb 20, 2026.
- Warning letter: Eden Health International Inc. dba Eden. FDA, Jun 8, 2026.
- Bulk drug substances nominated for use in compounding under section 503A (categories document). FDA, May 14, 2026.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA, May 14, 2026.
- FDA peptides do-not-compound list update (2026). Frier Levitt, Apr 2026.
- Determination that Geref (sermorelin acetate) products were not withdrawn from sale for reasons of safety or effectiveness. FDA, Federal Register, Mar 4, 2013.
- Current healthcare-associated infection situations. CDC, Sep 15, 2026.
- 2026 Prohibited List. World Anti-Doping Agency, Sep 2025.
- Warning letter: Royal Peptides LLC. FDA, Aug 24, 2026.
- Warning letter: USApeptide.com. FDA, Feb 26, 2025.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. FDA, Oct 1, 2026.
- Drug Trials Snapshots: Vyleesi. FDA, Jun 21, 2019.
- PCAC final summary minutes, Oct 29, 2024. FDA, Oct 29, 2024.
- Compounding and the FDA: questions and answers. FDA, Sep 16, 2025.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.